Investment Banking
Co-Lead Manager on Odyssey Therapeutics’ $289.8MM IPO
June 09, 2026
Oppenheimer & Co. Inc. acted as Co-Lead Manager on Odyssey Therapeutics’ $289.8MM Initial Public Offering and Co-Placement Agent on its $25.0MM Concurrent Private Placement
Odyssey Therapeutics, Inc. (NasdaqCM:ODTX), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 16,100,000 shares of its common stock at an initial public offering price of $18.00 per share.
In addition to the shares sold in the initial public offering described above, Odyssey announced a concurrent sale of 1,388,889 shares of common stock to an affiliate of TPG Life Sciences Innovations, at the initial public offering price of $18.00 per share, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended.
The gross proceeds to Odyssey from the initial public offering and concurrent private placement, without giving effect to the underwriters’ option to purchase additional shares in the initial public offering and before deducting underwriting discounts and commissions, placement agent fees and offering expenses payable by Odyssey, are expected to be approximately $314 million.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Name:
Dylan Gering
Title:Executive Director, Healthcare Life Sciences Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC